Singapore, June 1 -- Regenerative medicine is steadily redefining the future of cardiovascular care, with cell based therapies moving beyond experimental research into advanced clinical development. Among the companies leading this transition is CellProthera, which is preparing its stem cell therapy, ProtheraCytes(R), for pivotal Phase 3 evaluation in patients following myocardial infarction.

Strengthened by strategic leadership appointments and a focus on scalable manufacturing, the company is positioning itself to address one of the largest unmet needs in cardiology: preventing the progression to heart failure by repairing damaged cardiac tissue. In this Q&A with BioSpectrum Asia, Matthieu de Kalbermatten shares insights on the company...